Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Brainsway ( (BWAY) ).
On March 26, 2026, BrainsWay announced it had completed an additional $6 million milestone-based convertible loan investment in neuromodulation specialist Neurolief, triggered by U.S. FDA Premarket Approval for Neurolief’s Proliv Rx system for treatment-resistant major depressive disorder. The latest funding brings BrainsWay’s total investment in Neurolief to $11 million and strengthens a strategic partnership that combines BrainsWay’s in-clinic Deep TMS platform with Neurolief’s at-home neurostimulation devices.
BrainsWay’s management highlighted that Proliv Rx could expand the company’s total addressable market by reaching patients who cannot easily access Deep TMS clinics, while offering synergistic commercial opportunities. Neurolief, which is ramping up commercialization of Proliv Rx and holds Veterans Affairs Federal Supply Schedule pricing for both Proliv Rx and its migraine device Relivion MG, gains additional capital support and potential future equity funding, while BrainsWay retains a call option to acquire all of Neurolief, underscoring its push to consolidate its position in the fast-growing brain neuromodulation market.
The most recent analyst rating on (BWAY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved financial performance (profitability inflection, high gross margins, strong cash generation, and low leverage) and supportive technical strength (price above key moving averages with positive momentum). Earnings call tone and raised guidance add confidence, while valuation (P/E ~23.6 and no dividend yield provided) is the main moderating factor.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd., listed on Nasdaq and the Tel Aviv Stock Exchange, is a global medical technology company focused on advanced noninvasive neurostimulation treatments for mental health disorders. Its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform is FDA-cleared for major depressive disorder, obsessive-compulsive disorder and smoking addiction, with additional clinical trials under way in various psychiatric, neurological and addiction indications.
Average Trading Volume: 210,440
Technical Sentiment Signal: Buy
Current Market Cap: $561.5M
For an in-depth examination of BWAY stock, go to TipRanks’ Overview page.